References
- AltamuraACBoboWVMeltzerHYFactors affecting outcome in schizophrenia and their relevance for psychopharmacological treatmentInt Clin Psychopharmcol2007225249267
- LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
- SalimiKJarskogLFLiebermanJAAntipsychotic drugs for first-episode schizophrenia: a comparative reviewCNS Drugs2009231083785519739694
- KasperSDo we need another atypical antipsychotic?Eur Neuropsychopharmacol200818Suppl 3S146S15218511242
- CarpenterWTJrConleyRRBuchananRWBreierATammingaCAPatient response and resource management: another view of clozapine treatment of schizophreniaAm J Psychiatry199515268278327755110
- KaneJMAntipsychotic medication in the treatment of schizophreniaIsr J Psychiatry Relat Sci199532130377542642
- HaddadPMSharmaSGAdverse effects of atypical antipsychotics: differential risk and clinical implicationsCNS Drugs2007211191193617927296
- WeidenPJEPS profiles: the atypical antipsychotics are not all the sameJ Psychiatr Pract2007131132417242588
- NasrallahHA review of the effect of atypical antipsychotics on weightPsychoneuroendocrinology200328Suppl 1S83S96
- SuvisaariJMSaarniSIPeräläJMetabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population surveyJ Clin Psychiatry20076871045105517685741
- LindenmayerJPCzoborPVolavkaJChanges in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychoticsAm J Psychiatry2003160229029612562575
- MackinPBishopDWatkinsonHGallagherPFerrierINMetabolic disease and cardiovascular risk in people treated with antipsychotics in the communityBr J Psychiatry2007191232917602121
- HaddadPMWieckAAntipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and managementDrugs200464202291231415456328
- MeaneyAMSmithSHowesODO’BrienMMurrayRMO’KeaneVEffects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophreniaBr J Psychiatry200418450350815172944
- KraepelinELectures on Clinical PsychiatryNew York, NYWilliam Wood & Co1904 Lecture III: Dementia praecox2129
- GreenMFKernRSBraffDLMintzJNeurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?Schizophr Bull20002611913610755673
- WeinbergerDRGallhoferBCognitive function in schizophreniaInt Clin Psychopharmacol199712S29S369352344
- TollefsonGDCognitive function in schizophrenic patientsJ Clin Psychiatry19965731398941169
- BrewerWWoodSPhillipsLGeneralized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosisSchizophr Bull20063253855516782759
- AddingtonJAddingtonDNeurocognitive and social functioning in schizophreniaSchizophr Bull19992517318210098920
- GreenMFWhat are the functional consequences of neurocognitive deficits in schizophreniaAm J Psychiatry19961533213308610818
- HarveyPDParrellaMWhiteLMohsRCDavidsonMDavisKLConvergence of cognitive and adaptive decline in late-life schizophreniaSchizophr Res19993577849988843
- MortimerAMCognitive function in schizophrenia – Do neuroleptics make a differencePharmacol Biochem Behav1997567897959130306
- CleghornJMKaplanRDSzechtmanBSzechtmanHBrownGMNeuroleptic drug effects on cognitive function in schizophreniaSchizophr Res199032112191980613
- CutmoreTRHBeningerRJDo neuroleptics impair learning in schizophrenic patientsSchizophr Res199031731861980612
- FittonAHeelRCClozapine. A review of its pharmacological properties, and therapeutic use in schizophreniaDrugs1990407227472292234
- FultonBGoaKLOlanzapine, a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychosesDrugs1997532812989028746
- KaneJMTammingaCASertindole (serdolect): preclinical and clinical findings of a new atypical antipsychoticExp Opin Invest Drugs1997617291741
- AzorinJMStrubNLoftHA double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophreniaInt J Psychopharmacol2006214956
- MeltzerHYMcGurkSRThe effects of clozapine, risperidone, and olanzapine on cognitive function in schizophreniaSchizophr Bull19992523325510416729
- KeefeRSEBilderRMDavisSMNeurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trialArch Gen Psychiatry20076463364717548746
- HoffALFaustmanWOWienekeMThe effect of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatientsNeuropsychopharmacology1996153613698887990
- GoldbergTEGreenbergRDGriffinSJThe effect of clozapine on cognition and psychiatric symptoms in patients with schizophreniaBr J Psychiatry199316243488425138
- WuEQBirnbaumHGShiLThe economic burden of schizophrenia in the United States in 2002J Clin Psychiatry20056691122112916187769
- PerquinLSteinertTA review of the efficacy, tolerability and safety of sertindole in clinical trialsCNS Drugs200418Suppl 2S19S30
- van KammenDPMcEvoyJPTargumSDKardatzkeDSebreeTBA randomized, controlled, dose-ranging trial of sertindole in patients with schizophreniaPsychopharmacology (Berl)19961241681758935813
- FardeLNordströmALWieselFAPauliSHalldinCSedvallGPositron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effectsArch Gen Psychiatry19924975385441352677
- KapurSBarsoumSCSeemanPDopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQNeuropsychopharmacology200023559559811027926
- KasperSTauscherJKüfferleBSertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol – a 123I-IBZM SPECT studyPsychopharmacology (Berl)199813643673739600582
- MooreNHigher cardiovascular mortality with sertindole in ADROIT: a signal not confirmedInt J Psychiatry Clin Pract20026Suppl 1S3S9
- MooreNHallGSturkenboomMMannRLagnaouiRBegaudBBiases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindolePharmacoepidemiol Drug Saf200312427128112812006
- PezawasLQuinerSMoertlDEfficacy, cardiac safety, and tolerability of sertindole: a drug surveillanceInt Clin Psychopharmacol200015420721410954060
- WehnertAThe European Post-marketing Observational Serdolect® (EPOS) project: increasing our understanding of schizophrenia therapyInt Clin Psychopharmacol199813Suppl 3S27S309690967
- WiltonLVHeeleyELPickeringRMShakirSAComparative study of mortality rates and cardiac dysrythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapineJ Psychopharmacol20011512012611448085
- HyttelJArntJCostallBPharmacological profile of the atypical neuroleptic sertindoleClin Neuropharmacol199215Suppl 1 Pt A267A268A
- BundgaardCLarsenFKreilgaardMBrennumLTOlsenCKPharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance responseBiopharm Drug Dispos200930420922019475539
- WatanabeMHaginoYThe atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatumEur J Pharmacol19993671192310082260
- WarnerJPBarnesTRHenryJAElectrocardiographic changes in patients receiving neuroleptic medicationActa Psychiatr Scand19969343113138712033
- ShenWWThe metabolism of atypical antipsychotic drugs: an updateAnn Clin Psychiatry199911314515810482125
- OzekiYFujiiKKurimotoNQTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201034240140520079791
- MauriMCVolonteriLSColasantiAFiorentiniADe GaspariIFBareggiSRClinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical responseClin Pharmacokinet200746535938817465637
- DavisASThe pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methodsHum Exp Toxicol199817126776809988372
- DriciMDWangWXLiuXKWoosleyRLFlockhartDAProlongation of QT interval in isolated feline hearts by antipsychotic drugsJ Clin Psychopharmacol19981864774819864081
- HaleASA review of the safety and tolerability of sertindoleInt Clin Psychopharmacol199813Suppl 3S65S709690973
- AgelinkMWMajewskiTWurthmannCEffects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapineJ Clin Psychopharmacol200121181311199953
- GuryCCanceilOIariaPAntipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmiaEncephale2000266627211217540
- ThomsenMBVoldersPGStenglMElectrophysiological safety of sertindole in dogs with normal and remodeled heartsJ Pharmacol Exp Ther2003307277678412966159
- EckardtLBreithardtGHaverkampWElectrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongationJ Pharmacol Exp Ther20023001647111752098
- TitierKGirodetPOVerdouxHAtypical antipsychotics: from potassium channels to torsade de pointes and sudden deathDrug Saf2005281355115649104
- TitierKCanalMDéridetEDetermination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practiceToxicol Appl Pharmacol20041991526015289090
- BaptistaTKinNMBeaulieuSde BaptistaEAObesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectivesPharmacopsychiatry200235620521912518268
- SpinaEde LeonJMetabolic drug interactions with newer antipsychotics: a comparative reviewBasic Clin Pharmacol Toxicol2007100142217214606
- TaylorDPharmacokinetic interactions involving clozapineBr J Psychiatry19971711091129337943
- BhanaNFosterRHOlneyRPloskerGLOlanzapine: an updated review of its use in the management of schizophreniaDrugs200161111116111217867
- SakamotoKNakamuraYAikohSMetabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolismXenobiotica19952512132713438719908
- DanielWAKotMWojcikowskiJInfluence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomesPol J Pharmacol20035561055106114730101
- WongSLLinnenPMackRGrannemanGREffects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteersBiopharm Drug Dispos19971865335419267685
- HaduchAWojcikowskiJDanielWADirect effects of neuroleptics on the activity of CYP2A in the liver of ratsPharmacol Rep200557686787116382210
- EreshefskyLPharmacokinetics and drug interactions: update for new antipsychoticsJ Clin Psychiatry199657Suppl 11S12S25
- HaduchAOgorkaTBoksaJDanielWAInteractions between neuroleptics and CYP2C6 in rat liver – in vitro and ex vivo studyPharmacol Rep200557687287716382211
- WongSLLockeCStaserJGrannemanGRLack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteersPsychopharmacology (Berl)199813532362419498726
- WongSLGrannemanGRModeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studiesJ Pharm Sci199887121629163110189278
- WongSLMenacherrySMulfordDSchmitzPJLockeCGrannemanGRPharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal functionEur J Clin Pharmacol19975232232279218930
- WongSLCaoGMackRJGrannemanGRThe effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteersJ Clin Pharmacol19973711105610619505999
- ZimbroffDLKaneJMTammingaCAControlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study GroupAm J Psychiatry199715467827919167505
- DanielDGWozniakPMackRJMcCarthyBGfor the Sertindole Study GroupLong-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophreniaPsychopharmacol Bull19983461699564200
- HaleAAzorinJMKasperSSertindole improves both the positive and negative symptomcs of schizophrenia: resuts of a Phase III trialInt J Psychiatry Clin Pract2000415562
- KaneJMPotkinSGDanielDGBuckleyPA double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophreniaJ Clin Psychiatry2010In press
- KomossaKRummel-KlugeCHungerHSertindole versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev2009152CD00675219370652
- SteinertTHaugerBEckardtJSchmidPClinical observations of sertindole in 53 hospitalised patients with psychotic disordersClin Drug Investig20052517983
- TammingaCAMackRAGrannemanGRSilberCJKashkinKBSertindole in the treatment of psychosis in schizophrenia: efficacy and safetyInt Clin Psychopharmacol199712Suppl 1S29S359179641
- MooreNLagnaouiRToumiMBegaudBSuicide and sudden death during treatment with atypical neuroleptics: a comparison of sertindole, olanzapine, and risperidoneSchizophr Res199936356357
- SturkenboomMCJMPicelliGMooreNMortality during use of sertindole and other antipsychotics in the Netherlands and Belgium [abstract 273]Pharmacoepidemiol Drug Safety200110S1S164
- MurdochDKeatingGMSertindole: a review of its use in schizophreniaCNS Drugs200620323325516529528
- PeuskensJTanghojPMittouxAOutcome of the Sertindole Cohort Prospective (SCoP) study: all-cause mortalityPoster presented at: the 15th Winter Workshop in Psychoses2009 Nov 15–18Barcelona, Spain
- LançonCToumiMSapinCHansenKThe Sertindole Safety Survey: a retrospective analysis under a named patient use programme in EuropeBMC Psychiatry 200885718638382
- LindströmEFardeLEberhardJHaverkampWQTc interval prolongation and antipsychotic drug treatments: focus on sertindoleInt J Neuropsychopharmacol20058461562915963244
- AtmacaMYavuzkirMMermiOTopuzMKanmazETezcanEEffect of sertindole on QTc interval in patients with schizophreniaNeurosci Lett200844211318639380
- HarriganEPMiceliJJAnzianoRA randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibitionJ Clin Psychopharmacol200424626914709949
- RedfernWSCarlssonLDavisASRelationships between preclinical cardiac electrophysiology, clinical QT interval prolongation, and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug developmentCardiovasc Res200358324512667944
- TaylorDMAntipsychotics and QT prolongationActa Psychiatr Scand2003107859512534433
- NielsenJGraffCHardahlTSertindole causes distinct electrocardiographic T-wave morphology changesEur Neuropsychopharmacol2009191070270719457646
- PerquinLTreatment with the new antipsychotic sertindole for late-occurring undesirable movement effectsInt Clin Psychopharmacol200520633533816192844
- SacchettiEValsecchiPQuetiapine, olanzapine, and clozapine in the treatment of tardive dyskinesiaJ Clin Psychopharmacol200318357359
- NewcomerJWMetabolic syndrome and mental illnessAm J Manag Care200713Suppl 7S170S17718041878
- De HertMMittouxAHeYPeuskensJMetabolic parameters in the short- and long-term treatment of schizophrenia with sertindole and risperidonePoster presented at: the 15th Winter Workshop in Psychoses2009 Nov 15–18Barcelona, Spain
- LohCLeckbandSGMeyerJMTurnerERisperidone-induced retrograde ejaculation: case report and review of the literatureInt Clin Psychopharmacol200419211111215076020
- SmithPJTalbertRLSexual dysfunction with antihypertensive and antipsychotic agentsClin Pharm1986553733842872991
- SkarsfeldtTDifferential effect of antipsychotics on place navigation of rats in the Morris water mazePsychopharmacology (Berl)19961241261338935807
- DidriksenMKreilgaardMArntJSertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatmentEur J Pharmacol20065421310811516797002
- DidriksenMSkarsfeldtTArntJReversal of PCP-induced learning and memory deficits in the Morris’ water maze by sertindole and other antipsychoticsPsychopharmacology (Berl)2007193222523317406859
- GoetghebeurPDiasRComparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat – a back translational studyPsychopharmacology (Berl)20092021328729319002439
- RodeferJSNguyenTNKarlssonJJArntJReversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychoticsNeuropsychopharmacology200833112657266618094666
- BurnhamKEBaxterMGBaintonJRActivation of 5-HT6 receptors facilitates attentional set shiftingPsychopharmacology2010208132119902184
- HatcherPDBrownVJTaitDS5-HT6 receptor antagonists improve performance in an attentional set-shifting task in ratsPsychopharmacology (Berl)200518125325915846482
- MitchellESNeumaierJF5-HT6 receptors: a novel target for cognitive enhancementPharmacol Ther200510832033316005519
- UptonNChuangTTHunterAJVirleyDJ5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s diseaseNeurotherapeutics2008545846918625457
- GallhoferBJaansonPMittouxATanghøjPLisSKriegerSCourse of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidolPharmacopsychiatry200740627528618030652
- BuchsbaumMSHaznedarMNewmarkREFDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophreniaSchizophr Res20091141316117119683417
- LacroixLPDawsonLAHaganJJHeidbrederCA5HT-6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortexSynapse20045115816414618683
- MeltzerHYBaldessariniRJReducing the risk for suicide in schizophrenia and affective disordersJ Clin Psychiatry2003641122112914628990
- MeltzerHYAlphsLGreenAIClozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)Arch Gen Psychiatry2003601829112511175
- CrocqMAMittouxATanghojPNaberDSuicide in a prospective cohort of patients with schizophrenia treated with sertindole or risperidonePoster presented at: the 15th Winter Workshop in Psychoses2009 Nov 15–18Barcelona, Spain
- LindenmayerJPLiu-SeifertHKulkarniPMMedication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry200970799099619497244
- AzorinJMMurteiraSHansenKToumiMEvaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysisBMC Psychiatry 200881618366634
- SchuckPvan den AmeeleHJaansonPRyckmansVHawleyCCase histories illustrating the utility of sertindole in clinical practiceCNS Drugs200418Suppl 2S31S40
- LublinHEberhardJLevanderSCurrent therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychoticsInt Clin Psychopharmacol200520418319815933479
- PeuskensJIntroduction to sertindole in clinical practiceCNS Drugs200418Suppl 21415461311
- RodeferJSThe effects of antipsychotics on reversing PCP-induced deficits in a rodent attentional set-shifting taskSchizophr Res200681S130S131
- HochmanMMcCormickDCharacteristics of published comparative effectiveness studies of medicationsJAMA20103031095195820215609